TurboVax Inc. was founded on June 26, 2023, by Dr. Kishore R. Alugupalli, PhD, Associate professor of Microbiology, and Immunology, Thomas Jefferson University, Philadelphia, PA, USA. Dr. Alugupalli currently is the fulltime CEO of TurboVax Inc, and is interested in commercialization of a ground-breaking vaccine adjuvant named Turbo. The major goal of TurboVax Inc is to partner with vaccine manufacturing or vaccine developing companies and organizations. The incorporation of Turbo as an adjuvant will significantly improve the immunogenicity and efficacy of polysaccharide subunit vaccines and help prevent bacterial infections globally.

TurboVax Inc.

Org chart

Teams

Offices